Skip to main content
Premium Trial:

Request an Annual Quote

Weakness in Proteomics and Life Science Research Contributes to Disappointing Q2 for Waters


Funding cuts for government and academic researchers led to weakened demand for tools for "cutting-edge proteomics and life science research," said Waters CEO Douglas Berthiaume during a conference call discussing the company's second-quarter results.

That, along with orders delayed in anticipation of the launch of Waters' new Synapt G2-S mass spectrometer at the American Society for Mass Spectrometry annual meeting in June, led to slowing demand in Q2 for the company's existing Synapt machines, Berthiaume said.

He noted that the firm expects the government and academic markets will continue to be flat but that its "innovative new systems, especially in high-end mass spectrometry, will allow [Waters] to compete favorably within this more challenging funding environment."

"The second-half results will probably be most affected by the Synapt G2-S," Berthiaume said. "We're expecting significant shipments of that at the end of the third quarter into the fourth quarter."

For the quarter Waters posted $447.6 million in revenue, up 14 percent from $391.1 million a year ago, but short of Wall Street's consensus estimate of $451.1 million.

The company also fell short of Wall Street's earnings-per-share expectations as net income for the quarter came in at $100.1 million, or $1.07 per share. On an adjusted basis EPS was $1.08, below analysts' expectations of $1.14. The company's profit for the prior year's second quarter was $84.9 million, or $.90 per share.

Waters' R&D spending rose 11 percent to $23.0 million from $20.8 million a year ago.

It ended the second quarter with $1.12 billion in cash, cash equivalents, and short-term investments.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.